查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1766079

全球脑炎药物市场：预测至 2032 年－按疾病类型、给药途径、病原体、通路、最终用户和地区进行分析

Encephalitis Treatment Market Forecasts to 2032 - Global Analysis By Disease Type (Primary encephalitis and Secondary encephalitis), Route of Administration, Causative Agent, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

据 Stratistics MRC 称，2025 年全球脑炎药物市场价值为 239 亿美元，预计到 2032 年将达到 389 亿美元，预测期内的复合年增长率为 7.2%。脑炎药物是指针对脑炎的医疗管理和治疗性介入。脑炎是一种脑部炎症，通常由病毒感染引起，但也可能由细菌、真菌或自体免疫原因引起。治疗旨在减少脑部发炎、控制症状和预防併发症。通常会提供支持性治疗，包括抗病毒药物和抗生素、减轻肿胀的皮质类固醇、用于抽搐的抗惊厥药物以及补液和氧气疗法。在严重的情况下，可能需要住院和加护治疗。早期诊断和及时治疗对于最大限度地减少长期神经病变和改善患者预后至关重要，特别是对于儿童和老年人等弱势群体。

据国家感染疾病控制中心称，日本脑炎是印度的一个主要健康问题。

病毒性脑炎发生率上升

病毒性脑炎发生率的上升正对脑炎药物市场产生积极影响，推动了对先进诊断工具、抗病毒疗法和支持性护理解决方案的需求。认知度的提高和早期诊断促使医疗保健提供者投资于更优的治疗通讯协定，从而促进了市场成长。此外，政府和医疗机构正在资助研发，以改善治疗效果。因此，对及时有效管理脑炎的日益重视正激励製药公司进行创新，进一步拓宽市场前景。

医疗费用高昂

脑炎治疗费用高昂是市场成长的主要障碍，尤其是中低收入地区。昂贵的抗病毒药物、加护治疗、长期住院和復健服务给患者和医疗保健系统带来了经济负担，阻碍了及时诊断和治疗，导致干预延迟和预后不良。因此，经济障碍限制了患者获得先进治疗方案的机会，限制了市场扩张，并为医疗保健提供者带来了重大挑战。

诊断和治疗的进展

诊断和治疗方法的进步极大地推动了市场的成长。快速且准确的诊断工具的发展使得早期发现成为可能，从而改善了治疗效果。抗病毒和免疫调节疗法的创新正在提高患者的康復率并减少长期併发症。个人化医疗和基于生物标记的治疗正在进一步完善治疗方法。这些进步不仅提高了临床效率，还鼓励增加研究投入，最终扩大市场规模并改善全球脑炎患者的照护。

复杂诊断

脑炎诊断复杂且耗时，对治疗市场构成重大挑战。诊断延迟或不准确会导致治疗延迟、患者预后恶化并增加併发症风险。由于缺乏先进诊断工具，尤其是在资源匮乏的地区，早期发现也受到阻碍。这种复杂性增加了医疗成本，阻碍了及时干预，从而限制了市场成长，从而影响了脑炎治疗方案的整体有效性。

COVID-19的影响

COVID-19 疫情对医疗体系造成巨大压力，并将资源重新用于病毒防治，扰乱了脑炎治疗市场。诊断延迟、就诊人数减少以及临床试验中断，影响了及时治疗。然而，随着人们对 COVID-19 相关神经系统併发症的认识不断提高，脑炎研究也重新受到关注。这种双重影响为脑炎诊断和治疗的发展带来了短期挑战和长期机会。

预计病毒部分在预测期内将是最大的。

由于单纯疱疹病毒、日本脑炎和西尼罗河病毒等病毒感染疾病的流行，预计病毒学领域将在预测期内占据最大的市场占有率。病毒性脑炎认知度的提高和早期诊断的提高，推动了对有效抗病毒药物和支持性治疗的需求。此外，政府在疫苗接种和疫情控制方面的措施和资金投入也促进了市场扩张。控制病毒性脑炎疫情的迫切性进一步加速了先进脑炎治疗方案的研究、开发和应用。

抗生素领域预计在预测期内以最高复合年增长率成长

抗生素领域预计将在预测期内实现最高成长，因为它能够有效治疗细菌性脑炎，尤其是在次发性脑炎病例中。医疗保健提供者的认知度不断提高以及针对性抗生素治疗的进步正在推动需求成长。此外，频谱抗生素和诊断工具的日益普及使得及时治疗成为可能，减少了併发症，并提高了患者的康復率。这些因素共同推动了市场扩张，使抗生素成为脑炎药物策略的重要组成部分。

比最大的地区

在预测期内，亚太地区预计将占据最大的市场占有率，这得益于医疗保健意识的不断增强、病毒感染疾病的流行以及先进医疗设施的普及。政府加强医疗基础设施和扩大疫苗接种计划的措施正在进一步推动市场扩张。此外，研发投入的增加以及有效抗病毒疗法的普及也有助于改善治疗效果。人口增长和对更优质神经系统护理的需求也在推动该地区市场的成长。

复合年增长率最高的地区：

预计北美地区在预测期内的复合年增长率最高。这得归功于人们日益增强的认知度以及蚊媒病毒感染疾病和疾病引起的脑炎病例的不断增加。强而有力的政府倡议和科研资金推动了研发和早期诊断的增加。该地区受益于最尖端科技的获取以及大型製药公司的所在地。此外，由于对高效抗病毒治疗和疫苗的需求日益增长，美国和加拿大的市场也在不断扩张。

免费客製化服务

本报告的所有订阅者均可享有以下免费自订选项之一：

  • 公司简介
    • 对其他公司（最多 3 家）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 市场机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

第五章全球脑炎药物市场（依疾病类型）

  • 原发性脑炎
  • 次发性脑炎

6. 全球脑炎治疗市场（按治疗剂）

  • 抗病毒药物
  • 类固醇注射
  • 抗生素
  • 免疫球蛋白治疗
  • 血浆置换
  • 其他治疗方法

7. 全球脑炎药物市场（依给药途径）

  • 口服药物
  • 肠外药物
  • 其他给药途径

8. 全球脑炎药物市场（按病原体）

  • 病毒性的
  • 自体免疫
  • 细菌
  • 其他病原体

9. 全球脑炎药物市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 10 章全球脑炎药物市场（按最终用户）

  • 医院
  • 研究中心
  • 诊所
  • 专业中心
  • 其他最终用户

第 11 章全球脑炎药物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Pfizer Inc.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc（GSK）
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Abbott Laboratories
  • Basilea Pharmaceutica Ltd.
  • Melinta Therapeutics LLC
  • Bristol Myers Squibb
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Aurobindo Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Valneva SE
  • Bharat Biotech
  • BIKEN
  • Substipharm
Product Code: SMRC29934

According to Stratistics MRC, the Global Encephalitis Treatment Market is accounted for $23.9 billion in 2025 and is expected to reach $38.9 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Encephalitis treatment refers to the medical management and therapeutic interventions used to address encephalitis, an inflammation of the brain typically caused by viral infections, though bacterial, fungal, or autoimmune causes are also possible. Treatment aims to reduce brain inflammation, manage symptoms, and prevent complications. It often includes antiviral or antibiotic medications, corticosteroids to reduce swelling, anticonvulsants for seizures, and supportive care such as hydration and oxygen therapy. In severe cases, hospitalization and intensive care may be necessary. Early diagnosis and prompt treatment are crucial to minimize long-term neurological damage and improve patient outcomes, especially in vulnerable populations such as children and the elderly.

According to the National Center for Vector Borne Diseases Control, Japanese encephalitis is a significant health concern in India.

Market Dynamics:

Driver:

Rising Incidence of Viral Encephalitis

The rising incidence of viral encephalitis is positively impacting the encephalitis treatment market by driving demand for advanced diagnostic tools, antiviral therapies, and supportive care solutions. Increasing awareness and early diagnosis are pushing healthcare providers to invest in better treatment protocols, boosting market growth. Moreover, governments and healthcare institutions are funding research and development efforts to improve treatment efficacy. This growing focus on timely and effective management of encephalitis is encouraging pharmaceutical companies to innovate, further expanding the market landscape.

Restraint:

High Cost of Treatment

The high cost of encephalitis treatment significantly hampers market growth, especially in low- and middle-income regions. Expensive antiviral medications, intensive care, prolonged hospitalization, and rehabilitation services place a financial burden on patients and healthcare systems. This deters timely diagnosis and treatment, leading to delayed interventions and poor outcomes. As a result, the affordability barrier restricts access to advanced treatment options, limiting market expansion and posing a major challenge to healthcare providers.

Opportunity:

Advancements in Diagnostics & Therapeutics

Advancements in diagnostics and therapeutics are significantly driving growth in the market. The development of rapid and accurate diagnostic tools enables early detection, improving treatment outcomes. Innovations in antiviral and immunomodulatory therapies are enhancing patient recovery rates and reducing long-term complications. Personalized medicine and biomarker-based treatments are further refining therapeutic approaches. These advancements not only improve clinical efficiency but also encourage greater investment in research, ultimately expanding the market and offering improved care for encephalitis patients globally.

Threat:

Complex Diagnosis

The complex and time-consuming process of diagnosing encephalitis poses a significant challenge to the treatment market. Delayed or inaccurate diagnosis can lead to postponed treatment, worsening patient outcomes and increasing the risk of complications. Limited access to advanced diagnostic tools, especially in low-resource settings, further hampers early detection. This complexity restricts market growth by increasing healthcare costs and deterring timely intervention, thereby impacting the overall effectiveness of encephalitis treatment solutions.

Covid-19 Impact

The COVID-19 pandemic disrupted the encephalitis treatment market by straining healthcare systems and diverting resources toward managing the virus. Delays in diagnosis, reduced hospital visits, and interruptions in clinical trials affected timely treatment. However, increased awareness of neurological complications linked to COVID-19 also led to a renewed focus on encephalitis research. This dual impact created both short-term challenges and long-term opportunities for advancements in encephalitis diagnostics and therapies.

The viral segment is expected to be the largest during the forecast period

The viral segment is expected to account for the largest market share during the forecast period, due to rising prevalence of viral infections such as herpes simplex, Japanese encephalitis, and West Nile virus. Increasing awareness and early diagnosis of viral encephalitis have boosted the demand for effective antiviral drugs and supportive therapies. Moreover, government initiatives and funding for vaccination and outbreak control contribute to market expansion. The urgency to manage viral outbreaks further accelerates research, development, and adoption of advanced encephalitis treatment options.

The antibiotics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the antibiotics segment is predicted to witness the highest growth rate, as it offers effective solutions against bacterial causes of the disease, particularly in secondary encephalitis cases. Increased awareness among healthcare providers, advancements in targeted antibiotic therapies are driving demand. Additionally, the growing availability of broad-spectrum antibiotics and supportive diagnostic tools is enhancing timely treatment, reducing complications, and improving patient recovery rates. These factors collectively support market expansion and reinforce antibiotics as a critical component in encephalitis care strategies

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to rising healthcare awareness, increasing prevalence of viral infections, and improved access to advanced medical facilities. Government initiatives aimed at strengthening healthcare infrastructure and expanding immunization programs are further supporting market expansion. Additionally, increasing investments in R&D and the availability of effective antiviral therapies are contributing to enhanced treatment outcomes. The growing population and demand for better neurological care are also fueling the region's market growth positively.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, because of growing awareness and an increase in encephalitis cases brought on by viral infections and illnesses spread by mosquitoes. Drug development and early diagnosis have increased because to strong government initiatives and research funding. The area gains by having access to cutting-edge technologies and being home to significant pharmaceutical enterprises. Furthermore, the market is expanding in the US and Canada due to rising need for efficient antiviral treatments and vaccinations.

Key players in the market

Some of the key players profiled in the Encephalitis Treatment Market include Pfizer Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Basilea Pharmaceutica Ltd., Melinta Therapeutics LLC, Bristol Myers Squibb, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Pharma Limited, Hikma Pharmaceuticals PLC, Valneva SE, Bharat Biotech, BIKEN and Substipharm.

Key Developments:

In May 2025, Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc., for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

In October 2024, TRIANA Biomedicines, Inc. announced that it has entered into a strategic collaboration and licensing agreement with Pfizer to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.

Disease Types Covered:

  • Primary encephalitis
  • Secondary encephalitis

Treatments Covered:

  • Antiviral agents
  • Steroid injections
  • Antibiotics
  • Immunoglobulin therapy
  • Plasmapheresis
  • Other Treatments

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Routes of Administration

Causative Agents Covered:

  • Viral
  • Autoimmune
  • Bacterial
  • Pathogens

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

End Users Covered:

  • Hospitals
  • Research Centers
  • Clinics
  • Specialty Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Encephalitis Treatment Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Primary encephalitis
  • 5.3 Secondary encephalitis

6 Global Encephalitis Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Antiviral agents
  • 6.3 Steroid injections
  • 6.4 Antibiotics
  • 6.5 Immunoglobulin therapy
  • 6.6 Plasmapheresis
  • 6.7 Other Treatments

7 Global Encephalitis Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Other Routes of Administration

8 Global Encephalitis Treatment Market, By Causative Agent

  • 8.1 Introduction
  • 8.2 Viral
  • 8.3 Autoimmune
  • 8.4 Bacterial
  • 8.5 Pathogens

9 Global Encephalitis Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Online Pharmacies
  • 9.4 Retail Pharmacies

10 Global Encephalitis Treatment Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Research Centers
  • 10.4 Clinics
  • 10.5 Specialty Centers
  • 10.6 Other End Users

11 Global Encephalitis Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Sanofi S.A.
  • 13.3 F. Hoffmann-La Roche Ltd.
  • 13.4 GlaxoSmithKline plc (GSK)
  • 13.5 Merck & Co., Inc.
  • 13.6 Teva Pharmaceutical Industries Ltd.
  • 13.7 Abbott Laboratories
  • 13.8 Basilea Pharmaceutica Ltd.
  • 13.9 Melinta Therapeutics LLC
  • 13.10 Bristol Myers Squibb
  • 13.11 Novartis AG
  • 13.12 Johnson & Johnson
  • 13.13 Eli Lilly and Company
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Aurobindo Pharma Limited
  • 13.16 Hikma Pharmaceuticals PLC
  • 13.17 Valneva SE
  • 13.18 Bharat Biotech
  • 13.19 BIKEN
  • 13.20 Substipharm

List of Tables

  • Table 1 Global Encephalitis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Encephalitis Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 3 Global Encephalitis Treatment Market Outlook, By Primary encephalitis (2024-2032) ($MN)
  • Table 4 Global Encephalitis Treatment Market Outlook, By Secondary encephalitis (2024-2032) ($MN)
  • Table 5 Global Encephalitis Treatment Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 6 Global Encephalitis Treatment Market Outlook, By Antiviral agents (2024-2032) ($MN)
  • Table 7 Global Encephalitis Treatment Market Outlook, By Steroid injections (2024-2032) ($MN)
  • Table 8 Global Encephalitis Treatment Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 9 Global Encephalitis Treatment Market Outlook, By Immunoglobulin therapy (2024-2032) ($MN)
  • Table 10 Global Encephalitis Treatment Market Outlook, By Plasmapheresis (2024-2032) ($MN)
  • Table 11 Global Encephalitis Treatment Market Outlook, By Other Treatments (2024-2032) ($MN)
  • Table 12 Global Encephalitis Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 13 Global Encephalitis Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 14 Global Encephalitis Treatment Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 15 Global Encephalitis Treatment Market Outlook, By Other routes of Administration (2024-2032) ($MN)
  • Table 16 Global Encephalitis Treatment Market Outlook, By Causative Agent (2024-2032) ($MN)
  • Table 17 Global Encephalitis Treatment Market Outlook, By Viral (2024-2032) ($MN)
  • Table 18 Global Encephalitis Treatment Market Outlook, By Autoimmune (2024-2032) ($MN)
  • Table 19 Global Encephalitis Treatment Market Outlook, By Bacterial (2024-2032) ($MN)
  • Table 20 Global Encephalitis Treatment Market Outlook, By Other Pathogens (2024-2032) ($MN)
  • Table 21 Global Encephalitis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 22 Global Encephalitis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 23 Global Encephalitis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 24 Global Encephalitis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 25 Global Encephalitis Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Encephalitis Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 27 Global Encephalitis Treatment Market Outlook, By Research Centers (2024-2032) ($MN)
  • Table 28 Global Encephalitis Treatment Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 29 Global Encephalitis Treatment Market Outlook, By Specialty Centers (2024-2032) ($MN)
  • Table 30 Global Encephalitis Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.